Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients

Am J Ther. 2021 Jul 5;28(5):e592-e596. doi: 10.1097/MJT.0000000000001412.

Authors

Scott J Morin¹, Chinmay Jani¹, Arashdeep Rupal¹, Harpreet Singh¹, Daniel Bourque², Robert C Colgrove²

Affiliations

¹ Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
² Department of Infectious Diseases, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.

Abstract

Supplemental Digital Content is Available in the Text.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab